VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate at multiple ...

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Ad ...

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord inj ...

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced its Board of Directors has unanimously appointed Adam Rogers, MD, as President and Chief Executive Officer (CEO), effective immediately. Dr. Rogers will continue leading the C ...

Core Viewpoint - NervGen Pharma Corp. has appointed Dr. Adam Rogers as President and CEO, reflecting the Board's confidence in his leadership and vision for the company's future in neuroreparative therapeutics for spinal cord injury [1][2][3] Company Leadership - Dr. Rogers has been recognized for his decisive execution during his tenure as Interim CEO, including the successful Nasdaq listing and positioning of NVG-291 for late-stage development [2][3] - The Board believes Dr. Rogers embodies the leadership qualities necessary for advancing novel therapies, emphasizing his background as a physician and biotech executive [3] Company Mission and Product Development - NervGen's mission is to transform the lives of individuals with spinal cord injuries by enabling the nervous system to repair itself [6][7] - The lead therapeutic candidate, NVG-291, has shown durable improvement in function and quality of life in clinical studies and is preparing for a Phase 3 trial [7] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA, highlighting its potential in addressing significant unmet medical needs [7] Stock Options and Compensation - In connection with Dr. Rogers' appointment, the company granted 717,891 stock options, with specific vesting schedules and exercise prices [3]

Core Viewpoint - NervGen Pharma Corp. is set to ring the closing bell at the Nasdaq Stock Market on January 22, 2026, marking a significant milestone in the company's growth and evolution as a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1][3]. Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) by enabling the nervous system to repair itself [4]. - The company's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function, independence, and quality of life in individuals with chronic SCI [4]. - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI, with ongoing enrollment in a Phase 1b/2a clinical study and preparations for a Phase 3 trial [4]. Leadership and Recognition - Adam Rogers, MD, Chairman and Interim Chief Executive Officer, emphasized the honor of participating in the Nasdaq closing bell ceremony and acknowledged the support from shareholders, collaborators, and families involved in clinical research [3]. - The event will be livestreamed from the Nasdaq MarketSite Tower, showcasing the company's mission and achievements to a broader audience [3].

Core Viewpoint - NervGen Pharma Corp. has received approval for its common shares to be listed on Nasdaq, marking a significant milestone in its development as a biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1] Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) [2] - The lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvements in function, independence, and quality of life in chronic SCI patients [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI [2] Recent Developments - The listing on Nasdaq is expected to enhance market visibility, improve liquidity, and broaden the shareholder base, ultimately driving long-term shareholder value as the company advances NVG-291 [1] - Recent Phase 1b/2a CONNECT SCI Study data revealed unprecedented durable improvements in function and quality of life for individuals with chronic SCI, with significant enhancements in upper-limb corticospinal signaling [1] - The company plans to conduct a U.S. FDA End-of-Phase 2 meeting in early 2026 to discuss the development and registration pathway for NVG-291 [1]

Core Viewpoint - NervGen Pharma Corp. has filed a registration statement with the SEC to enhance its strategic initiatives and growth strategy in developing neuroreparative therapeutics for spinal cord injury and other neurological disorders [1][2]. Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on creating innovative therapies that enable the nervous system to repair itself in cases of neurotrauma and neurological diseases [4]. - The company is currently evaluating its lead candidate, NVG-291, in a Phase 1b/2a clinical study called CONNECT SCI for spinal cord injury [4]. Registration Statement Details - The registration statement filed with the SEC is not yet effective, meaning no securities can be sold or offers accepted until it becomes effective [2]. - The registration statement contains detailed information about the company and is available on EDGAR and from the company directly [3].

Core Viewpoint - NervGen Pharma Corp. is amending the exercise price of its 2022 Warrants from US$1.75 to the Canadian equivalent of C$2.44 to align with its functional currency and simplify accounting treatment, while all other terms remain unchanged [1] Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury and other neurological disorders [1][3] - The company is evaluating its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study for spinal cord injury [3] Product Information - NVG-291 is a first- and potential best-in-class therapeutic peptide that enables the nervous system to repair itself, with exclusive worldwide rights held by NervGen [2] - The technology for NVG-291 is licensed from Case Western Reserve University, based on studies showing its preclinical efficacy in promoting neurorepair and functional improvement in spinal cord injury models [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Designation from the EMA for spinal cord injury [2]

Core Viewpoint - NervGen Pharma continues to demonstrate significant progress in the development of NVG-291, a potential first-in-class treatment for spinal cord injury, with promising clinical data supporting its efficacy in restoring function and improving quality of life for patients [3][4][6]. Pipeline Progress - The expanded CONNECT SCI Study data shows that NVG-291 leads to durable improvements in function, independence, and quality of life, with participants reporting a 2.6-fold greater mean improvement in GRASSP Total Score and a 3.7-fold greater mean improvement in GRASSP Quantitative Prehension compared to placebo [4][6]. - The FDA confirmed multiple regulatory pathways for NVG-291's approval, highlighting the significant unmet medical need for spinal cord injury treatments [6][8]. Financial Progress - On November 19, 2025, the company completed a non-brokered private placement, raising approximately US$10 million, which will support its anticipated Nasdaq listing [9]. - As of September 30, 2025, NervGen had cash and investments totaling US$11.4 million, a decrease from US$17.3 million at the end of 2024, primarily due to operational activities related to the CONNECT SCI Study [10]. Corporate Progress - In July 2025, the company appointed Adam Rogers, MD, as Interim Chief Executive Officer and Randall Kaye, MD, as Chief Medical Advisor to strengthen its leadership for the late-stage development of NVG-291 [10][12]. - The company is focused on advancing NVG-291 in collaboration with the spinal cord injury community and the FDA [3][8]. Research & Development Expenses - R&D expenses for the three months ended September 30, 2025, were US$4.4 million, consistent with the same period in 2024, reflecting higher costs for drug supply procurement and regulatory requirements [11]. General and Administrative Expenses - G&A expenses decreased to US$1.7 million for the three months ended September 30, 2025, from US$2.8 million in the same period in 2024, due to reduced non-cash stock-based compensation and lower legal and professional expenses [14]. Net Loss - The net loss for the three months ended September 30, 2025, was US$4.2 million, or US$0.06 per share, an improvement from a net loss of US$5.3 million, or US$0.08 per share, in the same period in 2024 [15]. About NVG-291 - NVG-291 is a therapeutic peptide that enables the nervous system to repair itself, with exclusive worldwide rights held by NervGen. The technology is based on studies showing its efficacy in promoting neurorepair and functional improvement in spinal cord injury models [16]. About NervGen - NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurotrauma and neurologic diseases, with its lead candidate NVG-291 currently in the Phase 1b/2a CONNECT SCI Study [17].